A requirement for SOCS-1 and SOCS-3 phosphorylation in Bcr-Abl-induced tumorigenesis.

Suppressors of cytokine signaling 1 and 3 (SOCS-1 and SOCS-3) are inhibitors of the Janus tyrosine kinase (JAK)/signal transducers and activators of transcription (STAT) pathway and function in a negative feedback loop during cytokine signaling. Abl transformation is associated with constitutive activation of JAK/STAT-dependent signaling. However, the mechanism by which Abl oncoproteins bypass SOCS inhibitory regulation remains poorly defined. Here, we demonstrate that coexpression of Bcr-Abl with SOCS-1 or SOCS-3 results in tyrosine phosphorylation of these SOCS proteins. Interestingly, SOCS-1 is highly tyrosine phosphorylated in one of five primary chronic myelogenous leukemia samples. Bcr-Abl-dependent tyrosine phosphorylation of SOCS-1 and SOCS-3 occurs mainly on Tyr 155 and Tyr 204 residues of SOCS-1 and on Tyr 221 residue of SOCS-3. We observed that phosphorylation of these SOCS proteins was associated with their binding to Bcr-Abl. Bcr-Abl-dependent phosphorylation of SOCS-1 and SOCS-3 diminished their inhibitory effects on the activation of JAK and STAT5 and thereby enhanced JAK/STAT5 signaling. Strikingly, disrupting the tyrosine phosphorylation of SOCS-1 or SOCS-3 impaired the expression of Bcl-X(L) protein and sensitized K562 leukemic cells to undergo apoptosis. Moreover, selective mutation of tyrosine phosphorylation sites of SOCS-1 or SOCS-3 significantly blocked Bcr-Abl-mediated tumorigenesis in nude mice and inhibited Bcr-Abl-mediated murine bone marrow transformation. Together, these results reveal a mechanism of how Bcr-Abl may overcome SOCS-1 and SOCS-3 inhibition to constitutively activate the JAK/STAT-dependent signaling, and suggest that Bcr-Abl may critically requires tyrosine phosphorylation of SOCS-1 and SOCS-3 to mediate tumorigenesis when these SOCS proteins are present in cells.

[1]  T. Holyoake,et al.  Kill one bird with two stones: potential efficacy of BCR-ABL and autophagy inhibition in CML. , 2011, Blood.

[2]  B. Ebert,et al.  The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. , 2011, Blood.

[3]  R. Moriggl,et al.  High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia. , 2011, Blood.

[4]  W. Priebe,et al.  Janus kinase 2 regulates Bcr–Abl signaling in chronic myeloid leukemia , 2010, Leukemia.

[5]  P. Rothman,et al.  Oncogenic E17K mutation in the pleckstrin homology domain of AKT1 promotes v-Abl-mediated pre-B-cell transformation and survival of Pim-deficient cells , 2010, Oncogene.

[6]  L. Hennighausen,et al.  Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia , 2010, EMBO molecular medicine.

[7]  S. Abdou,et al.  Prognostic relevance of 9q34 deletion and the suppressor of cytokine signalling‐1 in CML patients , 2010, International journal of laboratory hematology.

[8]  M. Waters,et al.  SOCS3 as a tumor suppressor in breast cancer cells, and its regulation by PRL , 2009, International journal of cancer.

[9]  J. Johnston,et al.  SOCS3 tyrosine phosphorylation as a potential bio-marker for myeloproliferative neoplasms associated with mutant JAK2 kinases , 2009, Haematologica.

[10]  Edward J Mcmanus,et al.  Deletion of the SOCS box of suppressor of cytokine signaling 3 (SOCS3) in embryonic stem cells reveals SOCS box-dependent regulation of JAK but not STAT phosphorylation. , 2009, Cellular signalling.

[11]  C. Murre,et al.  Suppression of E-protein activity interferes with the development of BCR-ABL-mediated myeloproliferative disease , 2008, Proceedings of the National Academy of Sciences.

[12]  L. Honigberg,et al.  Bruton's tyrosine kinase is not essential for Bcr-Abl-mediated transformation of lymphoid or myeloid cells , 2008, Leukemia.

[13]  P. Rothman,et al.  Pim-1 and Pim-2 kinases are required for efficient pre-B-cell transformation by v-Abl oncogene. , 2008, Blood.

[14]  A. Mottok,et al.  Somatic hypermutation of SOCS1 in lymphocyte-predominant Hodgkin lymphoma is accompanied by high JAK2 expression and activation of STAT6. , 2007, Blood.

[15]  C. Ar,et al.  The SOCS‐1 gene methylation in chronic myeloid leukemia patients , 2007, American journal of hematology.

[16]  Masato Kubo,et al.  SOCS proteins, cytokine signalling and immune regulation , 2007, Nature Reviews Immunology.

[17]  Mary Frances McMullin,et al.  The myeloproliferative disorder-associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3. , 2007, Blood.

[18]  B. Quesnel,et al.  Dormant tumor cells develop cross-resistance to apoptosis induced by CTLs or imatinib mesylate via methylation of suppressor of cytokine signaling 1. , 2007, Cancer research.

[19]  L. Flowers,et al.  Both the Suppressor of Cytokine Signaling 1 (SOCS-1) Kinase Inhibitory Region and SOCS-1 Mimetic Bind to JAK2 Autophosphorylation Site: Implications for the Development of a SOCS-1 Antagonist1 , 2007, The Journal of Immunology.

[20]  P. Murray.  The JAK-STAT Signaling Pathway: Input and Output Integration1 , 2007, The Journal of Immunology.

[21]  R. V. van Etten.  chronic myeloid , 2022 .

[22]  H. Kantarjian,et al.  Janus kinase 2: a critical target in chronic myelogenous leukemia. , 2006, Cancer research.

[23]  T. Mattfeldt,et al.  Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation. , 2005, Oncogene.

[24]  F. Sommerer,et al.  SOCS-3 is frequently methylated in head and neck squamous cell carcinoma and its precursor lesions and causes growth inhibition , 2005, Oncogene.

[25]  Kenichi Matsubara,et al.  Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma , 2005, Oncogene.

[26]  A. Yoshimura,et al.  Negative regulation of cytokine signaling and immune responses by SOCS proteins , 2005, Arthritis research & therapy.

[27]  C. Geisler,et al.  Constitutive SOCS-3 expression protects T-cell lymphoma against growth inhibition by IFNα , 2005, Leukemia.

[28]  T. Barth,et al.  [Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in MedB-1 mediastinal lymphoma line]. , 2004, Verhandlungen der Deutschen Gesellschaft fur Pathologie.

[29]  T. Barth,et al.  Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line. , 2005, Blood.

[30]  N. Danial,et al.  v-Abl signaling disrupts SOCS-1 function in transformed pre-B cells. , 2004, Molecular cell.

[31]  D. Hilton,et al.  Inhibitors of Cytokine Signal Transduction* , 2004, Journal of Biological Chemistry.

[32]  D. Colomer,et al.  The suppressor of cytokine signaling-1 is constitutively expressed in chronic myeloid leukemia and correlates with poor cytogenetic response to interferon-alpha. , 2004, Haematologica.

[33]  Biao He,et al.  SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[34]  Jan-Gowth Chang,et al.  Epigenetic alteration of the SOCS1 gene in chronic myeloid leukaemia , 2003, British journal of haematology.

[35]  J. Herman,et al.  SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma. , 2003, Blood.

[36]  S. Fujita,et al.  Constitutive expression of SOCS3 confers resistance to IFN-alpha in chronic myelogenous leukemia cells. , 2002, Blood.

[37]  D. Hilton,et al.  Regulation of Jak2 through the Ubiquitin-Proteasome Pathway Involves Phosphorylation of Jak2 on Y1007 and Interaction with SOCS-1 , 2002, Molecular and Cellular Biology.

[38]  M. Nawijn,et al.  Pim serine/threonine kinases regulate the stability of Socs-1 protein , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[39]  Yan Wang,et al.  Involvement of Jak2 tyrosine phosphorylation in Bcr–Abl transformation , 2001, Oncogene.

[40]  J. Herman,et al.  SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity , 2001, Nature Genetics.

[41]  S. Minoguchi,et al.  The SOCS Box of SOCS-1 Accelerates Ubiquitin-dependent Proteolysis of TEL-JAK2* , 2001, The Journal of Biological Chemistry.

[42]  J. Johnston,et al.  Tyrosine-phosphorylated SOCS-3 inhibits STAT activation but binds to p120 RasGAP and activates Ras , 2001, Nature Cell Biology.

[43]  J. Griffin,et al.  Bcr/Abl activates transcription of the Bcl-X gene through STAT5. , 2000, Blood.

[44]  N. Danial,et al.  JAK-STAT signaling activated by Abl oncogenes , 2000, Oncogene.

[45]  J. G. Zhang,et al.  The conserved SOCS box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteasomal degradation. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[46]  P. Rothman,et al.  Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients. , 1997, Journal of immunology.

[47]  R. V. van Etten,et al.  P210 and P190BCR/ABL Induce the Tyrosine Phosphorylation and DNA Binding Activity of Multiple Specific STAT Family Members* , 1996, The Journal of Biological Chemistry.

[48]  C. Sawyers,et al.  Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. , 1996, Oncogene.